symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
SCLX,1.82,0.816232,784359,279313565,0,1.21-16.9,-0.02,Scilex Holding Company,USD,0001820190,,,NASDAQ Capital Market,NASDAQ,Drug Manufacturersâ€”General,https://www.scilexholding.com,"Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.",Mr. Jaisim  Shah,Healthcare,US,100,650-516-4310,960 San Antonio Road,Palo Alto,CA,94303,,0,https://financialmodelingprep.com/image-stock/SCLX.png,2021-03-05,True,False,True,False,False
